Swedish pharmaceutical company Orexo AB (STO:ORX) (OTCQX:ORXOY) on Tuesday announced a collaboration with Abera Bioscience to develop nasal powder vaccines using Orexo's AmorphOX technology.

AmorphOX has the potential to improve the stability and efficacy of Abera's vaccine candidates, particularly for intranasal delivery.

The partnership aims to develop powder-based intranasal influenza vaccine candidates, leveraging Abera's innovative vaccine platform and Orexo's drug delivery technology.

The collaboration is funded by Abera through various grants, primarily from the Coalition for Epidemic Preparedness Innovation (CEPI).